Jun‐ichi Kouyama

A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors

Yoshihito Uchida, Jun‐ichi Kouyama, Kayoko Naiki et al. · PLoS ONE · 2014 · 55 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism

Yoshihito Uchida, Jun‐ichi Kouyama, Kayoko Naiki et al. · Hepatology Research · 2016 · 36 citations

Life Sciences, Infectious Diseases, Pharmacology +17

NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir

Hayato Uemura, Yoshihito Uchida, Jun‐ichi Kouyama et al. · Journal of Gastroenterology · 2019 · 35 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

Yoshihito Uchida, Masamitsu Nakao, Shohei Tsuji et al. · Journal of Medical Virology · 2019 · 35 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

Shohei Tsuji, Yoshihito Uchida, Hayato Uemura et al. · Hepatology Research · 2019 · 23 citations

Medicine, Infectious Diseases, Internal Medicine +17